10x Genomics, Inc. (NASDAQ:TXG) Holdings Lowered by Northern Trust Corp

Northern Trust Corp trimmed its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 5.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 561,666 shares of the company’s stock after selling 31,923 shares during the period. Northern Trust Corp’s holdings in 10x Genomics were worth $8,066,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Signaturefd LLC lifted its holdings in shares of 10x Genomics by 424.6% during the fourth quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock valued at $26,000 after purchasing an additional 1,452 shares during the last quarter. Blue Trust Inc. lifted its holdings in shares of 10x Genomics by 73.1% during the fourth quarter. Blue Trust Inc. now owns 3,075 shares of the company’s stock valued at $44,000 after purchasing an additional 1,299 shares during the last quarter. Sound Income Strategies LLC lifted its holdings in shares of 10x Genomics by 65.2% during the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock valued at $48,000 after purchasing an additional 1,330 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of 10x Genomics during the fourth quarter valued at $52,000. Finally, SRS Capital Advisors Inc. lifted its holdings in shares of 10x Genomics by 817.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 4,853 shares of the company’s stock valued at $70,000 after purchasing an additional 4,324 shares during the last quarter. 84.68% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on TXG. UBS Group reduced their price objective on 10x Genomics from $14.00 to $12.00 and set a “neutral” rating for the company in a research note on Tuesday, May 13th. Stephens reissued an “overweight” rating and issued a $14.00 price objective on shares of 10x Genomics in a research note on Thursday. Canaccord Genuity Group reduced their price objective on 10x Genomics from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Monday, May 12th. Stifel Nicolaus reduced their price objective on 10x Genomics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Finally, Morgan Stanley reduced their price objective on 10x Genomics from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, 10x Genomics currently has a consensus rating of “Hold” and a consensus target price of $16.42.

10x Genomics Stock Performance

Shares of NASDAQ TXG opened at $9.39 on Monday. The firm has a market cap of $1.15 billion, a price-to-earnings ratio of -6.18 and a beta of 1.94. The business’s 50-day simple moving average is $8.77 and its 200-day simple moving average is $12.31. 10x Genomics, Inc. has a 52 week low of $6.78 and a 52 week high of $25.55.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.09. The business had revenue of $154.88 million for the quarter, compared to analyst estimates of $131.91 million. 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. The firm’s revenue for the quarter was down 2.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.50) EPS. As a group, equities research analysts forecast that 10x Genomics, Inc. will post -1.43 earnings per share for the current year.

Insider Activity

In other 10x Genomics news, insider Benjamin J. Hindson sold 4,573 shares of the firm’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $50,623.11. Following the sale, the insider now owns 335,324 shares of the company’s stock, valued at $3,712,036.68. This trade represents a 1.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Serge Saxonov sold 5,092 shares of the firm’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $11.07, for a total value of $56,368.44. Following the completion of the sale, the chief executive officer now directly owns 879,482 shares in the company, valued at $9,735,865.74. This trade represents a 0.58% decrease in their position. The disclosure for this sale can be found here. 9.39% of the stock is currently owned by insiders.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.